Nicolau DP - Search Results

1

Piperacillin/Tazobactam Dose Optimization in the Setting of Piperacillin/Tazobactam-susceptible, Carbapenem-resistant Pseudomonas aeruginosa: Time to Reconsider Susceptible Dose Dependent.

Gill CM, Nicolau DP; ERACE-PA Global Study Group. Gill CM, et al. Among authors: nicolau dp. Clin Ther. 2023 Jan;45(1):72-77. doi: 10.1016/j.clinthera.2022.12.004. Epub 2022 Dec 31. Clin Ther. 2023. PMID: 36593150 Free article.

2

Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis.

Kuti JL, Nightingale CH, Knauft RF, Nicolau DP. Kuti JL, et al. Among authors: nicolau dp. Clin Ther. 2004 Apr;26(4):493-501. doi: 10.1016/s0149-2918(04)90051-3. Clin Ther. 2004. PMID: 15189746 Clinical Trial.

3

Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem.

Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. Mattoes HM, et al. Among authors: nicolau dp. Clin Ther. 2004 Aug;26(8):1187-98. doi: 10.1016/s0149-2918(04)80001-8. Clin Ther. 2004. PMID: 15476901 Review.

4

Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program.

Maglio D, Kuti JL, Nicolau DP. Maglio D, et al. Among authors: nicolau dp. Clin Ther. 2005 Jul;27(7):1032-42. doi: 10.1016/j.clinthera.2005.07.004. Clin Ther. 2005. PMID: 16154482

5

Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.

Ellis JM, Kuti JL, Nicolau DP. Ellis JM, et al. Among authors: nicolau dp. Clin Ther. 2005 Nov;27(11):1820-30. doi: 10.1016/j.clinthera.2005.11.007. Clin Ther. 2005. PMID: 16368453

6

Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation.

Eagye KJ, Kuti JL, Dowzicky M, Nicolau DP. Eagye KJ, et al. Among authors: nicolau dp. Clin Ther. 2007 May;29(5):889-899. doi: 10.1016/j.clinthera.2007.05.018. Clin Ther. 2007. PMID: 17697907

7

Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?

Kim A, Sutherland CA, Kuti JL, Nicolau DP. Kim A, et al. Among authors: nicolau dp. Pharmacotherapy. 2007 Nov;27(11):1490-7. doi: 10.1592/phco.27.11.1490. Pharmacotherapy. 2007. PMID: 17963458

8

In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US Hospitals.

Eagye KJ, Kuti JL, Sutherland CA, Christensen H, Nicolau DP. Eagye KJ, et al. Among authors: nicolau dp. Clin Ther. 2009 Nov;31(11):2678-88. doi: 10.1016/j.clinthera.2009.11.021. Clin Ther. 2009. PMID: 20110010

9

Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.

Kim A, Kuti JL, Nicolau DP. Kim A, et al. Among authors: nicolau dp. Clin Ther. 2009 Nov;31(11):2765-78. doi: 10.1016/j.clinthera.2009.11.026. Clin Ther. 2009. PMID: 20110018

10

Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.

Koomanachai P, Bulik CC, Kuti JL, Nicolau DP. Koomanachai P, et al. Among authors: nicolau dp. Clin Ther. 2010 Apr;32(4):766-79. doi: 10.1016/j.clinthera.2010.04.003. Clin Ther. 2010. PMID: 20435246

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

751 results

Search Page

Filters